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ST-Segment Elevation Myocardial
Infarction Due to Early and Late Stent Thrombosis
A New Group of High-Risk Patients
Tania Chechi, MD,* Sabine Vecchio, MD,* Guido Vittori, MD,* Gabriele Giuliani, MD,*
Alessio Lilli, MD,* Gaia Spaziani, MD,† Lorenzo Consoli, MD,* Giorgio Baldereschi, MD,‡
Giuseppe G. L. Biondi-Zoccai, MD,§ Imad Sheiban, MD,§ Massimo Margheri, MD*
Florence and Turin, Italy
Objectives The aim of this retrospective study was to compare clinical and angiographic outcomes between patients pre-
senting with ST-segment elevation myocardial infarction (STEMI) due to stent thrombosis (ST) and de novo coro-
nary thrombosis.
Background There are limited data for procedural and mid-term outcomes of patients with ST presenting with STEMI.
Methods From January 2004 to March 2007, 115 definite ST patients were observed: 92 (80%) of them presented as
STEMI and were compared with a consecutive group of 98 patients with de novo STEMI. All patients underwent
primary percutaneous coronary intervention. Primary end points were successful angiographic reperfusion and
distal embolization. Major adverse cardiovascular and cerebrovascular events (MACCE), evaluated at 6-month
follow-up, were defined as death, nonfatal myocardial reinfarction, target vessel revascularization, and cerebro-
vascular accident.
Results Successful reperfusion rate was lower in patients with ST (p  0.0001), whereas distal embolization rate was
higher (p  0.01) in comparison with patients with de novo STEMI. Stent thrombosis proved to be an indepen-
dent predictor of unsuccessful reperfusion at propensity-adjusted binary logistic regression (odds ratio 6.8,
p  0.004). In-hospital MACCE rate was higher in patients with ST (p  0.003), whereas no differences were
observed at 6-month follow-up among hospital survivors between the 2 groups (p  0.7).
Conclusions Stent thrombosis identifies a subgroup of patients with STEMI with poor angiographic and early clinical out-
comes, suggesting that the management of these patients should be improved. (J Am Coll Cardiol 2008;51:
2396–402) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.01.070o
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wtent thrombosis (ST) is a recognized complication occur-
ing in 0.5% to 2.2% (1,2) of patients with coronary artery
isease treated by percutaneous coronary intervention (PCI)
ith stent implantation. Its occurrence is expected to
ncrease with the number of stent—in particular drug-
luting stent (DES)—implantation procedures done world-
ide. Clinical consequences of ST are generally cata-
trophic, including short-term mortality rates of up to 20%
o 25% and major myocardial infarction (MI) in 60% to 70%
f cases and 6-month mortality rates, among survivors of
T, of up to 20% to 25% (1). The presentation of ST is very
rom the *Cardiologia e Cardiologia Invasiva 2, A.O.U. Careggi, Florence, Italy;
School of Specialization of Cardiology, ‡Unit of Gerontology and Geriatric
edicine, University of Florence, Florence, Italy; and §Interventional Cardiology,
ivision of Cardiology, University of Turin, Turin, Italy.p
Manuscript received November 12, 2007; revised manuscript received December
1, 2007, accepted January 24, 2008.ften an ST-segment elevation myocardial infarction
STEMI) (3,4). Thus, ST represents a new, although
are, cause of STEMI that seems to be associated with
orse clinical outcomes than STEMI due to coronary
hrombosis. Repeat PCI is the commonly adopted treat-
ent in the ST setting. However, few scientific data are
vailable on procedural and midterm comparison of
See page 2403
TEMI due to ST versus de novo STEMI. We thus
etrospectively analyzed clinical presentation and angio-
raphic and clinical outcomes of 2 groups of consecutive
atients with STEMI caused by ST versus de novo coronary
hrombosis, all treated with primary PCI, to evaluate
hether patients with STEMI due to ST have higher
rocedural risk and worse clinical outcome.
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tudy population. From January 2004 to March 2007,
,068 PCIs were performed with 3,645 bare-metal stents
BMS) and 5,457 DES implanted. During this period 115
1.8%) STs were observed, of which 85 (2.3%) were DES
hromboses, whereas 30 (1.2%) were BMS thromboses.
inety-two (80%) of these STs presented as STEMI, and
ll were treated with primary PCI. We retrospectively
ompared this group of STs presenting with STEMI with a
onsecutive group of 98 patients with STEMI due to de novo
oronary thrombosis treated with primary PCI from January to
ctober 2004. Patients were identified in our database. Only
atients fulfilling clinical criteria for STEMI diagnosis (i.e.,
hest pain persisting 30 min associated with ST-segment
levation 0.1 mV in 2 continuous electrocardiographic
eads) and angiographic criteria for definite ST according to
he Academic Research Consortium definition (5) were in-
luded in our study.
rocedure. Primary PCI was performed according to stan-
ard care. Unfractioned heparin was given as an initial bolus
f 70 IU/kg, and additional boluses were administered
uring the procedure to achieve an activated clotting time of
50 to 300 s. All patients who had not taken aspirin before
resentation with STEMI received chewable aspirin at a
ose of 325 mg, followed by 100 mg/day by mouth indefi-
itely. Patients were loaded—if not previously taking clopi-
ogrel—with 300 or 600 mg clopidogrel before or immedi-
tely at the end of the procedure, followed by 75 mg/day for
t least 12 months. The use of glycoprotein IIb/IIIa inhib-
tors, thrombus removal, and embolic protection devices was
eft to the operator’s discretion. Mechanical assistance
evices (intra-aortic balloon pump and hemopump Impella
cute [Aachen, Germany]) were used when hemodynamic
upport was necessary (e.g., in the case of depressed systolic
unction and cardiogenic shock at presentation). Serial
amples for determination of cardiac biomarkers were rou-
inely collected in all patients 6, 12, and 24 h after the
rocedure.
Patients with ST at the time of the index procedure were
ecommended to take clopidogrel 75 mg/day in addition to
spirin for 1 month after BMS implantation, 12 months
fter DES implantation, and in case of acute coronary
yndrome (ACS).
ngiographic analysis. All PCI angiograms have been
nalyzed to assess a series of key angiographic data: 1) pre-
nd post-procedural antegrade coronary flow according to
he standard Thrombolysis In Myocardial Infarction
TIMI) criteria (6); 2) pre-procedural thrombus grade (TG)
ccording to the TIMI study group (7) (and in patients
resenting with TG 5, thrombus burden was also reclassi-
ed according to Sianos et al. [8]); 3) occurrence of
ngiographic distal embolization defined as occlusion with
n abrupt cut-off appearance at angiography of a branch of
he infarct related artery distal to the culprit lesion site; 4)
orrected TIMI frame count according to Gibson et al. (9), salculated in patients with post-
rocedural TIMI flow grade 2;
) post-procedural myocardial
lush grade according to van’t Hof
t al. (10); and 6) post-procedural
uantitative coronary angiography
nalysis performed, according to
stablished methods (11) with a
edicated software (CMS-QCA
, Medis, Leiden, the Nether-
ands), within the stented segment
nd the 5 mm proximal and distal to
he stent (total analysis segment).
linical follow-up. Information
egarding baseline clinical char-
cteristics, procedural details,
nd in-hospital events was ob-
ained from our database. At 6
onths from the procedure, data
egarding clinical status were ob-
ained by follow-up visit or tele-
hone interview.
nd points and definitions.
rimary end points identified for
nalysis in this study were the
ate of optimal angiographic reperfusion defined, according
o De Luca et al. (12), as the combination of post-
rocedural TIMI flow grade 3 and myocardial blush grade 2
r 3, and the rate of distal embolization. The occurrence of
ajor adverse cardiovascular and cerebrovascular events
MACCE) (i.e., death, nonfatal myocardial reinfarction,
arget vessel revascularization [TVR], and cerebrovascular
ccident) was evaluated during hospital stay and at 6-month
ollow-up. Nonfatal reinfarction was defined as new clinical
ymptoms or electrocardiographic changes associated with
n increase in the creatine kinase level more than twice the
pper normal limit with an increased creatine kinase-
yocardial band. In cases in which the creatine kinase level
ad not returned to normal values after the index event, a
econd peak was defined as repeat MI. Target vessel
evascularization was defined as any repeat revascularization
with PCI or coronary artery bypass grafting) of the infarct-
elated artery. According to the Academic Research Con-
ortium definition (5), ST was definite when there was
ngiographic confirmation of thrombus, with or without
essel occlusion, associated with the presence of an ACS
nd was classified into early (0 to 30 days, in particular acute
f it occurred within 24 h after the index procedure and
ubacute if it occurred between 2 and 30 days), late (31 to
60 days), or very late (360 days).
tatistical analysis. The SPSS version 12 software (SPSS
nc., Chicago, Illinois) was used for computations. Contin-
ous data were expressed as mean SD and were compared
ith the Student t test. Categorical variables were expressed
s percent (%) and were compared with either the chi-
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
HR  hazard ratio
MACCE  major adverse
cardiovascular and
cerebrovascular events
MI  myocardial infarction
PCI  percutaneous
coronary intervention
ST  stent thrombosis
STEMI  ST-segment
elevation myocardial
infarction
TG  thrombus grade
TIMI  Thrombolysis In
Myocardial Infarction
TVR  target vessel
revascularizationquare or Fisher exact test when the expected cell number in
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ifferences in baseline and clinical characteristics among the
study groups, a propensity score was built with a parsi-
onious approach and then forced into a multivariable
ogistic regression analysis (reported with odds ratios, 95%
onfidence intervals [CIs]) (13). Specifically, variables used
n the generation of the propensity score were age, gender,
ypertension, hypercholesterolemia, diabetes, smoking,
amily history of coronary artery disease, renal failure,
revious MI, anterior STEMI, time from symptoms onset
o intervention, shock at presentation, multivessel disease,
eft main disease, pre-procedural TIMI flow, pre-procedural
G, use of glycoprotein IIb/IIIa inhibitors, use of thrombus
emoval devices, and reference vessel diameter. A model also
ncluding left ventricular ejection fraction was specifically
sed as sensitivity analysis for in-hospital mortality predic-
ors. The Kaplan-Meier method was used to construct
urvival curves. The log-rank test was used to compare
urvival distributions. In addition, a Cox proportional haz-
rd analysis was performed for cumulative events at follow-
p, with results expressed as hazard ratios (HR; 95% CI).
or all tests, a 2-tailed p  0.05 was considered significant.
esults
atients’ characteristics. Baseline clinical characteristics
Table 1) did not differ significantly between the 2 groups,
xcept that patients in the ST group had higher rates of
enal failure, prior MI, and prior stroke (15.7% vs. 4.1%, p
0.008; 68.2% vs. 11.2%, p  0.0001; 7.1% vs. 0%, p 
.007, respectively) and fewer were smokers (26.5% vs. 48%,
 0.003). All patients (n  86) in the ST group reported
t least 1 episode of ST presenting with STEMI (92
TEMI overall). Most ST (64.1%) occurred within 30 days
rom the index procedure, which was performed in most
atients (88.4%) in the setting of an ACS; no difference in
ime from symptoms onset to intervention was found
etween patients with early and those with late or very late
T (179.0  47.7 min vs. 181.1  47.5 min, p  0.83).
aseline Clinical Characteristics
Table 1 Baseline Clinical Characteristics
STEMI
(n  98)
STEMI With ST
(n  86) p Value
Age (yrs) 62.9  10.3 66.0  11.9 0.06
Male 81 (82.7%) 68 (79.1%) 0.5
Cardiac risk factors
Hypertension 45 (45.9%) 44 (51.8%) 0.4
Diabetes mellitus 14 (14.3%) 21 (25.3%) 0.06
Hypercholesterolemia 34 (34.7%) 37 (43.4%) 0.2
Current smoker 47 (48.0%) 23 (26.5%) 0.003
Family history of CAD 35 (35.7%) 23 (26.5%) 0.2
Creatine 1.5 mg/dl 4 (4.1%) 13 (15.7%) 0.008
COPD 3 (3.1%) 8 (9.5%) 0.07
Prior MI 11 (11.2%) 59 (68.2%) 0.0001
Prior stroke 0 (0%) 6 (7.1%) 0.007a
AD  coronary artery disease; COPD  chronic obstructive pulmonary disease; MI  myocardial
nfarction; ST  stent thrombosis; STEMI  ST-segment elevation myocardial infarction.eventy events (76.1%) were STs in patients with DES,
hereas 22 (23.9%) were STs in patients with BMS; 62.7%
f patients were on double antiplatelet therapy at the
oment of ST, whereas 6.9% of patients reported an early
iscontinuation of the double antiplatelet therapy (owing to
he occurrence of bleeding, the diagnosis of cancer unknown
t the time of the first PCI, and the lack of compliance to
he therapy). A detailed description of this group of patients
s given in Table 2.
linical, angiographic, and procedural characteristics. As
hown in Table 3, patients in the ST group had a higher
lbeit statistically nonsignificant rate of cardiogenic shock at
resentation in comparison with patients in the other group
15.2% vs. 7.1%, p  0.07). Multivessel disease was signif-
cantly more common in the ST group (72.8% vs. 48%, p 
.0001), whereas there were no differences in MI location,
ime from onset of symptoms to PCI, and creatine phos-
hokinase values between the 2 groups. Procedural charac-
eristics, in particular use of glycoprotein IIb/IIIa inhibitors,
mbolic protection, thrombus removal, and mechanical
ssistance devices, did not differ between the 2 groups (only
se of angiojet was significantly higher in the ST group:
.5% vs. 0%, p  0.03).
ngiographic analysis. A lower successful reperfusion rate
nd a higher distal embolization rate were observed in
atients with ST (80.4% vs. 96.9%, p  0.0001; 6.5% vs.
%, p  0.01, respectively) (Table 4, Fig. 1). Indeed, ST
roved to be the only significant independent predictor of
nsuccessful reperfusion (odds ratio 6.8, 95% CI 1.8 to 25.2,
 0.004) at propensity-adjusted binary logistic regression.
n the ST group, shock at presentation was the only
ndependent predictor of unsuccessful reperfusion (p 
.01). Among patients with ST, reperfusion and distal
mbolization rates did not differ between patients with DES
nd those with BMS thromboses (77.3% vs. 90%, p  0.2
T Characteristics (n  92)
Table 2 ST Characteristics (n  92)
Definite ST (ARC definition) 92 (100%)
Thrombosis timing (ARC definition)
Early (30 days) 59 (64.1%)
Late (30–360 days) 14 (15.2%)
Very late (360 days) 19 (20.7%)
Clinical presentation at the index procedure 43 (46.5%)
MI (acute or sub-acute) 38 (41.9%)
UA/NSTEMI stable angina or silent ischemia 11 (11.6%)
Double antiplatelet therapy at the moment of stent thrombosis 62 (67.4%)
Early discontinuation of double antiplatelet therapy 6 (6.9%)
Stent
BMS 22 (23.9%)
DES 70 (76.1%)
Stent length 25.2  12.7
Stent diameter 2.8  0.3
RC  Academic Research Consortium; BMS  bare-metal stent; DES  drug-eluting stent; MI 
yocardial infarction; ST  stent thrombosis; UA/NSTEMI  unstable angina/non–ST-segment
levation myocardial infarction.nd 7.6% vs. 5%, p  0.7, respectively). The angiographic
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Table 4) with a higher rate of residual dissections (16.3%
s. 1%, p  0.0001) and a larger thrombus burden (TG 3
as present in 100% of patients in the ST group vs. 93.9%
f patients in the other group, p  0.01; even after
eclassification of the TG 5 after flow achievement, a higher
hrombus burden was still observed in the ST group: TG
3 was present in 95.6% of patients in the ST group vs.
6.7% of patients in the other group, p  0.03). However,
hen an acceptable antegrade flow (TIMI 2) was
chieved, corrected TIMI frame count did not differ be-
Clinical, Angiographic, and Procedural Characte
Table 3 Clinical, Angiographic, and Procedu
Anterior STEMI
Shock at presentation
Creatine phosphokinase max (U/l) 2
CK-MB max (ng/ml)
Time from symptoms onset to intervention (min)
Multivessel disease
Left main coronary artery
Left anterior descending artery
Left circumflex artery
Right coronary artery
Mechanical assistance devices
IABP
Hemopump Impella Acute
Thrombus aspiration
AngioJet
Export or Pronto devices
Distal protection
Glycoprotein antagonist
*In 3 patients the contemporary stent thrombosis within the left ante
these 3 patients either intra-aortic balloon pump (IABP) or Hemopum
CK-MB  creatine kinase–myocardial band; ST  stent thrombosis
ngiographic Analysis
Table 4 Angiographic Analysis
STEMI
(n  98)
STEMI With ST
(n  92) p Value
Pre-procedural TIMI flow 1 77 (78.6%) 69 (80%) 0.8
Post-procedural TIMI flow  3 95 (96.9%) 74 (80.4) 0.0001
Pre-procedural TG 3 92 (93.9%) 92 (100%) 0.01
Post-procedural myocardial
blush 1
1 (1.0%) 12 (13.0%) 0.001
Post-procedural cTFC* 24.2  12.6 21.2  9.4 0.1
Successful reperfusion 95 (96.9%) 74 (80.4%) 0.0001
Distal embolization 0 (0%) 6 (6.5%) 0.01
Residual dissection 1 (1.0%) 15 (16.3%) 0.0001
Post-procedural QCA analysis
RVD (mm) 3.2  0.4 2.9  0.3 0.0001
Lesion length (mm) 2.9  2.6 7.0  4.7 0.0001
MLD (mm) 2.9  0.4 2.0  0.7 0.0001
Diameter stenosis (%) 8.1  6.6 31.8  24.9 0.0001
Calculated in patients with post-procedural TIMI flow 2.
cTFC  corrected TIMI frame count; MLD  minimal lumen diameter; QCA  quantitative
oronary angiography; RVD  reference vessel diameter; ST  stent thrombosis; STEMI 
T-segment elevation myocardial infarction; TG  thrombus grade; TIMI  Thrombolysis In
yocardial Infarction.ween the 2 groups (21.2  9.4 in the ST group vs. 24.2 
2.6 in the other group, p  NS). The post-procedural
uantitative coronary angiography analysis showed in pa-
ients with ST a smaller diameter of the infarct-related
rtery (2.9  0.3 mm vs. 3.2  0.4 mm, p  0.0001) and
worse angiographic result expressed by a smaller min-
mal lumen diameter, a larger residual diameter stenosis,
nd a longer residual lesion length (2.0  0.7 mm vs. 2.9
0.4 mm, 31.8  24.9 mm vs. 8.1  6.6 mm, 7.0  4.7
Figure 1 Successful Reperfusion
Comparison of successful reperfusion rate between patients with ST-segment
elevation myocardial infarction (STEMI) due to de novo thromboses versus
stent thromboses. p  0.0001. Blue bar  STEMI without stent thrombosis
(ST); purple bar  STEMI with ST.
s
haracteristics
TEMI
 98)
STEMI With ST
(n  92) p Value
56.1%) 54 (58.7%) 0.7
7.1%) 14 (15.2%) 0.07
 2,629.8 2,285.1  3,905.9 0.2
 279.4 226.6  409.9 0.08
 87.4 179.7  47.1 0.5
48%) 67 (72.8%) 0.0001
0%) 1 (1.1%) 0.7
54.1%) 52 (56.5%)
15.3%) 18 (19.5%)*
30.6%) 24 (26.1%)
19.4%) 25 (27.2%) 0.2
19.4%) 25 (27.2%) 0.2
0%) 3 (3.3%)† 0.07
62.2%) 64 (69.6%) 0.3
0%) 6 (6.5%) 0.03
62.2%) 58 (63.1%) 0.9
0%) 0 (0%) —
90.8%) 76 (82.8%) 0.1
cending artery and left circumflex artery has been documented. †In
lla Acute were implanted.
 ST-elevation myocardial infarction.ristic
ral C
S
(n
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ll) (Table 4).
n-hospital and 6-month follow-up outcomes. Complete
ollow-up information was obtained in 100% of patients.
n-hospital and 6-month follow-up MACCE are presented in
able 5. Patients in the ST group had a higher in-hospital
ACCE rate (25.6% vs. 9.2%, p  0.003), with higher
ortality, reinfarction, and TVR rates but not stroke rate,
hich was similar between the 2 groups (17.4% vs. 7.1%,
 0.03; 8.1% vs. 1%, p  0.02; 9.3% vs. 2%, p  0.009;
% vs. 1%, p  0.3, respectively). The rate of subacute ST
as higher in patients with a previous ST (8.1% vs. 1%, p
.02); in particular, all of these STs presented with myo-
ardial reinfarction. Stent thrombosis did not prove to be an
ndependent predictor of in-hospital mortality (odds ratio
.9, 95% CI 0.5 to 15.6, p  0.2) at propensity-adjusted
inary logistic regression. Similar findings were obtained at
ensitivity analysis when forcing post-procedural left ven-
ricular ejection fraction in the multivariable propensity-
djusted model (p  0.2).
Among hospital survivors MACCE rate at 6-month
ollow-up did not differ between the 2 groups (11.3% in the
Figure 2 All-Cause Mortality and Cumulative MACCE Rate
Kaplan-Meier curve (6-month follow-up) for all-cause mortality and for cumulative m
event (MACCE) rate of patients with ST-segment elevation myocardial infarction (S
n-Hospital and 6-Month Follow-Up Outcomes
Table 5 In-Hospital and 6-Month Follow-Up Outcomes
In-Hospital Outcomes Hospi
STEMI
(n  98)
STEMI With ST
(n  86)
p
Value
STEMI
(n  91
Death 7 (7.1%) 15 (17.4%) 0.03 3 (3.3%
MI 1 (1%) 7 (8.1%) 0.02 0 (0%)
TVR (PCI or CABG) 2 (2%) 8 (9.3%) 0.009 6 (6.6%
Stroke 1 (1%) 0 (0%) 0.3 0 (0%)
MACCE 9 (9.2%) 22 (25.6%) 0.003 9 (9.9%
Stent thrombosis 1 (1%)* 7 (8.1%)* 0.02 0 (0%)†
Subacute stent thrombosis. †Late stent thrombosis.
CABG coronary artery bypass graft; MACCEmajor adverse cardiovascular and cerebrovascula
VR  target vessel revascularization; other abbreviations as in Table 1.T group vs. 9.9% in the other group, p  0.7). Only
yocardial reinfarction rate was higher in patients with ST
4.2% vs. 0%, p  0.04); 2 of these new MIs were
ubsequent to late ST, whereas 1 was subsequent to diffuse
ntrastent restenosis.
Kaplan-Meier survival curves show—considering the un-
djusted cumulative mortality and MACCE rate at 6
onths—significantly better survival and lower MACCE
ate in patients with STEMI due to de novo coronary
hromboses (p  0.04 and p  0.02, respectively) (Fig. 2).
owever, these comparisons were no longer significant at
ropensity-adjusted Cox analysis (HR for death  1.64,
5% CI 0.62 to 4.28, p  0.3; HR for MACCE  1.29,
5% CI 0.62 to 2.67, p  0.4).
Mortality and cumulative MACCE rates during hospital
tay and at 6-month follow-up were not different between
atients with DES and BMS thromboses (p  NS for all).
iscussion
linical consequences of ST are generally severe, including
hort-term mortality rates of up to 20% to 25% and MI in
dverse cardiovascular and cerebrovascular
due to de novo thromboses versus stent thromboses (STs).
rvivors 6-Month Outcomes Cumulative 6-Month Outcomes
STEMI With ST
(n  71)
p
Value
STEMI
(n  98)
STEMI With ST
(n  86)
p
Value
3 (4.2%) 0.7 10 (10.2%) 18 (20.9%) 0.04
3 (4.2%) 0.04 1 (1%) 6 (6.9%) 0.03
7 (9.8%) 0.4 7 (7.1%) 12 (13.9%) 0.1
0 (0%) — 1 (1%) 0 (0%) 0.3
8 (11.3%) 0.7 17 (17.3%) 27 (31.4%) 0.02
2 (2.8%)† 0.1 1 (1%) 9 (10.4%) 0.01
s; PCI percutaneous coronary intervention; STEMI ST-segment elevationmyocardial infarction;ajor a
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ssociated with ST could be related to the angiographic
uboptimal results often recorded after PCI for ST (4). The
ain finding of our study is consistent with this hypothesis.
ctually, we observed a significantly lower rate of successful
eperfusion and a higher rate of distal embolization in
atients with ST. We performed a binary logistic regression
nalysis with a propensity score adjustment to reduce the
isadvantage caused by the higher risk profile of patients
ith ST; ST itself resulted as an independent predictor of
nsuccessful reperfusion. Several issues could explain this
nding. The presence of a larger thrombus burden, recorded
n our study in patients with ST, is probably one of the most
mportant causes of poor procedural results, with worst
eperfusion indexes (i.e., higher rate of post-procedural
IMI flow 2 and myocardial blush grade 1) and higher
ate of distal embolization. Moreover, the presence of stent
nderexpansion, malapposition, residual dissection, and in-
ow/outflow disease that have just been well established by
ntravascular ultrasound as mechanical causes related to ST
oth for BMS and DES (1,14–16) might lead to a more
omplex PCI with consequently poor angiographic results.
ccordingly, we found more residual dissections and worse
ngiographic results at quantitative coronary angiography
nalysis in patients with ST. Unfortunately, because we did
ot perform intravascular ultrasound analysis in every patient
resenting with ST, data regarding stent malapposition—one
f the recognized causes of ST (14,16), in particular late and
ery late ST—are not available.
Patients with ST showed higher in-hospital mortality
han the other patients. However, ST was not found to be
n independent predictor of in-hospital mortality. The
igher in-hospital mortality observed in patients with ST
ould be related not only to the lower rate of successful
eperfusion but also to the worse baseline clinical character-
stics at the time of ST. In particular, we found that patients
ith ST had a higher albeit statistically nonsignificant rate
f cardiogenic shock at presentation. This finding could in
art explain the higher in-hospital mortality, because the
evelopment of cardiogenic shock during MI is character-
zed by a poor prognosis with an early mortality up to 50%
17) despite reperfusion therapy. Moreover, patients with
T had a high baseline risk profile due to a higher rate of
enal failure, prior stroke, prior MI, and multivessel disease,
hich could explain the higher rate of adverse outcome.
hese severe baseline characteristics are probably related to
he use of DES in an off-label setting. Most of the ST
bserved in our study (76.1%) were on DES, and in 87.5%
f cases DES were implanted in an off-label setting, which
eems to be associated with an increased risk of death as well
s of MI (18). In particular, the high rate of prior MI in the
T group is due to the high percentage (88.4%) of patients
reated with stent implantation at the index procedure for an
CS and for STEMI in 46.5% of the cases. Acute coronary
yndromes have been associated with increased rates of ST.
eal-world registries, which included patients with ACS dnd STEMI treated either with BMS or DES (4,19),
eported higher rates of ST than the ones observed after
lective stent implantation.
Patients with ST had a higher rate of nonfatal myocardial
einfarction either during hospital stay or at 6-month
ollow-up. All myocardial reinfarctions occurred after an ST
xcept 1 that was due to a diffuse intrastent restenosis that
ccurred after 3 months. It has been reported that ST recurs
n 12% of patients with a previous ST (4). Sianos et al. (8)
emonstrated that a large thrombus burden recorded during
TEMI is the strongest predictor of ST and that patients
ith a large thrombus burden experienced an extremely
igh infarct-related artery ST rate of 8.2%. Moreover, the
uboptimal angiographic results demonstrated by the high
esidual stenosis observed at the post-procedural quantita-
ive coronary angiography analysis could be explained by
ome residual thrombus burden or stent underexpansion,
hich are both identified as factors predisposing to ST
8,15). In particular, residual thrombus is an independent
redictor of early repeat MI in the PAMI (Primary Angio-
lasty in Myocardial Infarction) trial (20). Furthermore, ST
as been associated with an impaired response to antiplate-
et therapy, particularly in patients with ACS (21). Patients
ho experienced an ST are likely to be nonresponders to
ntiplatelet therapy, and this might lead to another throm-
otic event.
Among hospital survivors at 6-month follow-up, we
ound no difference in MACCE rate between the 2 groups.
oreover, no difference in the cumulative mortality and
ACCE rates was observed among patients with DES and
MS thromboses, although the small number of patients
oes not permit us to draw any definite conclusion.
All of these observations suggest that the management of
atients with ST might be improved in order to improve
linical outcomes. In recent years, a series of adjunctive
evices with the theoretical property of reducing distal
mbolization of thrombotic material have been conceived
nd entered the clinical practice. The negative or inconclu-
ive trials performed to date in the field of thrombotic
rotection/extraction devices in an acute MI setting might
e due to the selective enrollment of low-risk patients with
imited coronary thrombus (22,23). Therefore, the large
hrombus burden and the high risk of distal embolization
ssociated with ST makes it a promising field of application
or adjunctive devices. The preliminary results of the OP-
IMIST (The Outcome of PCI for stent-ThrombosIs
ultIcentre Study) trial have shown that patients without
nstable conditions (absence of shock) treated with throm-
ectomy devices had no excess of adverse clinical events and
ad a 5-fold improved rate of optimal coronary flow
estoration, thus supporting the safety and the efficacy of
uch devices in this high-risk scenario (24). Probably the use
f such devices in combination with an extensive use of
lycoprotein IIb/IIIa inhibitors might improve angiographic
esults. Moreover, extensive use of mechanical assistance
evices might be helpful in the treatment of slow or
n
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arge thrombus burden as well as for hemodynamic support,
hich is needed for the higher rate of cardiogenic shock
resent in ST setting. Finally, procedural and clinical
utcomes after ST could be improved by identification and
orrection of procedural issues leading to ST in order to
void its recurrence. Therefore, intravascular ultrasound
nalysis, performed either during or—even better—after the
cute phase of ST, should be considered to assess the
ptimal stent deployment and the presence of residual
issection.
tudy limitations. This is an observational study. We strived
o minimize confounding by means of propensity analysis, but
his approach cannot completely remove the risk of selection
ias. In addition, intravascular ultrasound data are not avail-
ble, thus limiting the ability to appraise the role of stent
xpansion, residual dissections, and malapposition that seem to
e predictors of ST according to the published scientific data.
oreover, we did not analyze the prevalence of antiplatelet
esistance, another major pathogenetic mechanism leading to
hrombosis and adverse cardiac events after PCI.
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